Announcement iconContinuing Accepting Applications for Admission !!
for the Spring Semester of the Academic Year 2019/2020

Prevalence of Sero-Molecular Markers of Hepatitis C and B Viruses among Patients with β-Thalassemia Major in Northern West Bank, Palestine

Authors: 
Kamal Dumaidi ,Amer Al-Jawabreh, Fekri Samarah , and Maha Rabayaa
ISSN: 
17129532
Journal Name: 
Canadian Journal of Infectious Diseases and Medical Microbiology
Volume: 
2018
Issue: 
18
Pages From: 
1
To: 
6
Date: 
Wednesday, September 5, 2018
Keywords: 
HCV, HBV, B-thalassemia
Abstract: 
Background. HCV and HBV present a great challenge in the management of β-thalassemia patients. Objective. +e present study aimed to determine the prevalence of both HBV and HCV in multitransfused-dependent β-thalassemia patients in northern West Bank, Palestine, using sero-molecular markers. Methods. Serum sample from 139 multitransfused β-thalassemia patients were tested for HBV and HCV markers including HBsAg, anti-HBc, anti-HBs, HBV-DNA, and anti-HCV and HCV-RNA. Demographic data and selected clinical parameters were collected by means of a questionnaire and from the patients’ medical files. Results and Conclusion. +e mean (±SD) age of patients was 18.1 years (±10.6). +e overall prevalence of the HCV was 10% (14/139), which is 50 times higher than the normal Palestinian population (0.2%). Of which, 3 were positive for anti-HCV alone, 7 positives for HCV-RNA alone, and 4 positives for both anti-HCV and PCR-RNA. On the other hand, low prevalence of HBV was detected at a level of 0.7% (1/139). Only one patient had HCV-HBV coinfection. Twenty-five patients (19%) were positive for anti- HBc, while 99 (71%) were immune with the anti-HBs level above 10 IU/mL. Anti-HBc was insignificantly high (P � 0.07) in HCVpositive cases. In conclusion, the prevalence of HCV among β-thalassemia patients is considered high compared to normal population. Determination of HCV prevalence should be based on the detection of both HCV-RNA and anti-HCV. On the contrary, HBV showed a low prevalence. A follow-up schedule and administration of booster dose of HBV vaccine is strongly recommended for β-thalassemia patients whose anti-HBs level <10 IU/ml.